• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes.

作者信息

Bates Eric R

机构信息

Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor.

出版信息

JAMA. 2020 Oct 27;324(16):1613-1615. doi: 10.1001/jama.2020.16238.

DOI:10.1001/jama.2020.16238
PMID:33107925
Abstract
摘要

相似文献

1
Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes.急性冠状动脉综合征抗血小板治疗的净不良临床事件
JAMA. 2020 Oct 27;324(16):1613-1615. doi: 10.1001/jama.2020.16238.
2
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.根据缺血和出血风险调整抗血小板治疗强度。
Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e004945. doi: 10.1161/CIRCOUTCOMES.118.004945.
3
Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?急性冠状动脉综合征的当代抗血小板治疗：氯吡格雷和替格瑞洛在疗效及停药方面存在差异吗？
Intern Med J. 2017 Nov;47(11):1298-1305. doi: 10.1111/imj.13595.
4
Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome.替格瑞洛与不同剂量氯吡格雷在急性冠状动脉综合征高危患者中的疗效与安全性比较
Int J Cardiol. 2017 Feb 1;228:275-279. doi: 10.1016/j.ijcard.2016.11.160. Epub 2016 Nov 9.
5
Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.在经皮冠状动脉介入治疗后急性冠脉综合征患者的早期和晚期转换为氯吡格雷的疗效和安全性。
Platelets. 2020;31(3):337-343. doi: 10.1080/09537104.2019.1609668. Epub 2019 May 1.
6
Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.糖尿病患者接受双联抗血小板治疗时的维生素 D 水平和血小板反应性。
Vascul Pharmacol. 2019 Sep;120:106564. doi: 10.1016/j.vph.2019.106564. Epub 2019 Jun 7.
7
High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.在采用当代药物洗脱支架和氯吡格雷或替格瑞洛治疗的急性冠脉综合征伴高出血风险患者中：来自 CHANGE DAPT 的研究结果。
Int J Cardiol. 2018 Oct 1;268:11-17. doi: 10.1016/j.ijcard.2018.03.116. Epub 2018 May 23.
8
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.普拉格雷（Efient®）联合经皮冠状动脉介入治疗急性冠状动脉综合征（TA182综述）：系统评价与经济学分析
Health Technol Assess. 2015 Apr;19(29):1-130. doi: 10.3310/hta19290.
9
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.基因型指导与双联抗血小板治疗急性冠脉综合征的成本效果分析。
Ann Intern Med. 2014 Feb 18;160(4):221-32. doi: 10.7326/M13-1999.
10
Ticagrelor induced neutrophilic eccrine hidradenitis: a unique adverse effect of a new antiplatelet drug.替格瑞洛诱发嗜中性小汗腺汗管炎：一种新型抗血小板药物的独特不良反应。
Postgrad Med J. 2019 May;95(1123):279-280. doi: 10.1136/postgradmedj-2019-136426. Epub 2019 Mar 29.

引用本文的文献

1
Are Bleeding Events Valid as a Surrogate Endpoint for Mortality in Cardiovascular Clinical Trials?出血事件能否作为心血管临床试验中死亡率的替代终点？
JACC Adv. 2023 May 26;2(3):100335. doi: 10.1016/j.jacadv.2023.100335. eCollection 2023 May.
2
Review of the Ticagrelor Trials Evidence Base.替格瑞洛试验证据基础回顾。
J Am Heart Assoc. 2024 Jun 4;13(11):e031606. doi: 10.1161/JAHA.123.031606. Epub 2024 May 28.
3
An "occlusive thrombosis-on-a-chip" microfluidic device for investigating the effect of anti-thrombotic drugs.
用于研究抗血栓药物效果的“芯片上闭塞性血栓形成”微流控装置。
Lab Chip. 2021 Oct 26;21(21):4104-4117. doi: 10.1039/d1lc00347j.